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Abstract
Background: Serum 25-hydroxyvitamin D [25(OH)D], the major circulating form of vitamin D used for evaluating
the vitamin D status of patients, has been associated with survival in a variety of cancers with conflicting evidence.
We aimed to investigate this association in newly diagnosed advanced non-small-cell lung cancer (NSCLC) patients.
Methods: This was a consecutive cohort of 359 newly diagnosed stages III-IV NSCLC patients who underwent a
baseline serum 25(OH)D evaluation prior to receiving any treatment at our institution between January 2008 and
December 2010. We used the vitamin D categories of “deficient (<20 ng/ml)” and “not deficient (> = 20 ng/ml)”. Cox
regression was used to evaluate the prognostic significance of serum 25(OH)D after adjusting for relevant confounders.
Results: Mean age at diagnosis was 57.4 years. Of the 359 patients, 151 (42.1 %) were deficient in vitamin D at the time
of diagnosis. The median survival in deficient and not deficient cohorts was 11.7 and 12.8 months respectively (p = 0.06).
Season of diagnosis, performance status, smoking status and hospital location significantly predicted vitamin D status. On
univariate Cox analysis, gender, stage of disease, hospital location, histologic subtype, subjective global assessment (SGA),
performance status, smoking status, body mass index and serum albumin were significantly associated with
survival (p <0.05 for all). On multivariate Cox analysis, six variables demonstrated statistically significant associations with
survival: stage of disease, hospital location, histologic subtype, SGA, smoking status and serum albumin (p <0.05 for all).
Serum vitamin D, which was borderline significant in univariate analysis, lost its significance in multivariate analysis.
Conclusions: We found season of diagnosis, performance status and smoking history to be predictive of vitamin D
status. Consistent with previously published research in advanced NSCLC, we did not find any significant association
between pre-treatment serum 25(OH)D and survival in our patients.
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Background
Vitamin D produced in the skin upon sun exposure
or ingested from the diet is converted in the liver to
25-hydroxyvitamin D [25(OH)D], the major circulat-
ing form of vitamin D used for evaluating the vitamin
D status of patients [1, 2]. 25(OH)D is hydroxylated
in the kidneys to form the biologically active metabolite
1,25-dihydroxyvitamin D [1,25(OH)2D] [3, 4]. Though
25(OH)D is not the active form of vitamin D, it is known
to be the best indicator of vitamin D status as it accurately
reflects vitamin D intake from all sources and has a half-
life of two to three weeks compared to only four hours for
the active form (1,25(OH)2D) [5].
Emerging evidence in the literature suggests an as-
sociation between serum 25(OH)D and survival in
several types of cancer, however, the evidence is not
conclusive with regard to the direction and strength
of association. While several studies have demon-
strated a positive association between serum vitamin
D and survival in multiple cancer types including gastric
[6], colorectal [7–11], breast [12, 13] and prostate [14],
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other studies have demonstrated a lack of such an associ-
ation [15–17]. Some studies have combined newly diag-
nosed and previously treated patients in the same analysis
[14], while others have found the vitamin D-survival asso-
ciation to become attenuated after adjusting for important
confounders [15]. Collectively, these studies indicate that
using a homogeneous patient population and adjustment
of important confounders are important aspects of study
design and data analysis respectively that should be taken
into account.
Specific to non-small cell lung cancer (NSCLC), there
have been 7 published studies evaluating the relationship
between serum 25(OH)D and survival with 3 of them
demonstrating positive association, 3 null association and
1 negative association. A study by Zhou et al. conducted
in 447 patients with early-stage NSCLC, found higher
levels of vitamin D to be associated with improved sur-
vival particularly among stage IB-IIB patients [18]. A Nor-
wegian study of 210 lung cancer patients that collected
serum samples shortly after diagnosis, observed that
higher serum 25(OH)D was associated with a statistically
significant longer survival time [19]. A study conducted in
16,693 men and women participating in the Third Na-
tional Health and Nutrition Examination Survey found
serum 25(OH)D concentrations to be inversely associated
with lung cancer mortality in nonsmokers; this association
was diminished among those with excess circulating vita-
min A [20]. Heist et al. conducted a study in 294 patients
with stage III-IV NSCLC and found no difference in sur-
vival by circulating vitamin D level quartiles [21]. A pro-
spective study by Turner et al. conducted in a relatively
homogeneous group of 148 surgically treated lung cancer
patients, found that pre-surgical levels of serum 25(OH)D
were not associated with either overall or lung-cancer spe-
cific mortality, although the study did report a protective
effect of higher vitamin D binding protein on lung-cancer
specific mortality [22]. The most recent findings on the
lack of a significant relationship between serum vitamin D
and survival comes from Anic et al. who investigated 500
male lung cancer cases (staged I–IV) in the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study.
Comparing highest to lowest quartiles, there was no statis-
tically significant association between serum 25(OH)D
and lung cancer survival [23]. Finally, a Chinese study of
87 NSCLC cases reported a negative association such that
higher serum 25(OH)D at diagnosis was associated with a
shorter survival time [24].
Given this variability in findings on the relationship be-
tween serum vitamin D and survival in NSCLC, additional
studies with large sample sizes are needed to better under-
stand the direction and strength of this association. We
investigated this association in a large homogenous group
of newly diagnosed advanced NSCLC patients treated at a
national network of oncology hospitals.
Methods
Study population
A consecutive series of 359 newly diagnosed stages III–IV
NSCLC patients treated at three Cancer Treatment
Centers of America® (CTCA) hospitals (located in Zion,
IL, Philadelphia, PA, and Tulsa, OK) between January
2008 and December 2010 was evaluated. We included a
consecutive case series of patients to minimize the prob-
ability of selection bias. The present study was conducted
according to the guidelines laid down in the Declaration
of Helsinki and was approved by the Midwestern Regional
Medical Center Institutional Review Board (IRB) at Can-
cer Treatment Centers of America®. The IRB waived the
need for informed consent because there was no direct
patient contact in this study. This study involved collec-
tion of existing data from patient records in such a man-
ner that subjects could not be identified, directly or
through identifiers linked to the subjects.
Vitamin D measurement
Serum samples were collected within 30 days of first
visit at our hospital, and prior to initiation of anticancer
therapy. Serum was collected at the laboratory, packed
in coolpacks and sent to the Laboratory Corporation of
America (Raleigh, NC) where a chemiluminescence
immune assay (CLIA, DiaSorin Liasion assay) was used
to measure 25(OH)D. Serum samples were incubated
with antivitamin-D coated microparticles and isoluminol
derivative-conjugated 25(OH)D before measurement of
chemiluminescent signals. Analysis was completed
within 48 h of collection. The DiaSorin Liasion
25(OH)D assay has been clinically validated to be com-
parable in accuracy and precision to the radioimmuno-
assay (RIA). This method uses the same particles used in
the DiaSorin RIA technique. Studies have found this to
be a rapid, accurate, and precise tool for the measure-
ment of serum 25(OH)D [25, 26].
Statistical analysis
Serum 25(OH)D was the primary independent variable
of interest. We used the categories “deficient (<20 ng/
ml)”, and “not deficient (> = 20 ng/ml)” in accordance
with previously published research in this area [12, 14].
A comparison of clinical and demographic characteris-
tics was made between the two vitamin D categories
using a two-sample t-test, a Mann Whitney test or a chi-
square test depending upon the underlying distribution
of the variables.
The primary endpoint was patient survival and was
defined as the time interval between the date of first
serum vitamin D assessment and the date of death from
any cause or the date of last contact/last known to be
alive. Patients were followed prospectively until December
2014. The Kaplan-Meier method was used to calculate
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survival. The log rank test statistic was used to evaluate
the equality of survival distributions across the 2 serum
25(OH)D groups. Clinical, demographic and serum
25(OH)D variables were evaluated using univariate Cox
proportional hazards models to determine which parame-
ters showed individual prognostic value for survival.
Multivariate Cox proportional hazards models were then
performed to evaluate the independent prognostic signifi-
cance of all variables that were evaluated in univariate
analysis. We adjusted for the following variables in the
multivariate analysis: age, gender, CTCA hospital, stage of
disease, Eastern Cooperative Oncology Group (ECOG)
performance status, body mass index (BMI), season of
diagnosis, serum albumin, smoking status, histologic sub-
type, and nutritional status as measured using Subjective
Global Assessment (SGA). Season of diagnosis was de-
fined as winter: December-February; spring: March-May;
summer: June-August, or fall: September-November. The
effect of serum 25(OH)D and other variables on patient
survival was expressed as hazard ratios (HRs) with 95 %
confidence intervals (CIs).
Cox regression with time-invariant covariates assumes
that the ratio of hazards for any two groups remains
constant in proportion over time. We checked this pro-
portional hazards (PH) assumption using a combination
of graphical and statistical testing procedures. First, we
examined log-minus-log plots for categorical predictors.
As a second approach, we ran an extended Cox model
with time-dependent covariates for continuous predic-
tors. Finally, a goodness-of-fit testing approach based on
Schoenfeld residuals was used to evaluate the PH
assumption.
Finally, to assess the possible influence of sample bias
on the results, as well as to investigate the stability of
the model coefficients, we performed a bias-corrected
and accelerated (BCa) bootstrap resampling procedure.
We generated 1000 samples, each the same size as the
original data set, by random selection with replacement.
Cox regression was then run separately on these 1000
samples to obtain robust estimates of the standard errors
of coefficients, and hence the p values and 95 % BCa CIs
of the model coefficients [27].
No formal sample size calculations were conducted for
this analysis. All reported P values are from two-sided tests.
All statistical analyses utilized SPSS version 20.0 (Inter-
national Business Machines, Armonk, New York, USA).
Results
Patient characteristics
Table 1 displays the baseline characteristics of our patients.
The median follow-up was 10.8 months. At the time of
this analysis, 293 (81.6 %) patients had expired while
66 (18.4 %) were considered censored. 163 (45.4 %)
patients were taking vitamin D supplements at the
time of diagnosis. 332 (92.5 %) patients received
chemotherapy, 191 (53.2 %) received radiation therapy
and 24 (6.7 %) received surgery at our institution. A
total of 172 (47.9 %) patients received both chemo-
therapy and radiation therapy at our institution.
Predictors of vitamin D status
Table 1 also describes the patient characteristics stratified
by the 2 categories of serum vitamin D (deficient and not
deficient). Season of diagnosis, ECOG performance status,
smoking status and CTCA hospital were the four variables
that demonstrated statistical significance (p <0.05). Pa-
tients who presented to us in the summer and fall months
were less likely to be deficient in vitamin D compared to
those who presented in winter and spring. The mean
(standard deviation [sd]) serum vitamin D levels were 24.7
(11.8), 31.2 (20.8), 22.3 (10.4) and 23.5 (14.1) nanograms
per milliliter (ng/ml) for summer, fall, winter and spring
months respectively. Patients with ECOG performance
scores of 0–1 were less likely to be deficient in vitamin D
compared to those with scores 2–4. Current smoking sta-
tus was associated with a greater prevalence of vitamin D
deficiency compared to past or no smoking history. Fi-
nally, patients diagnosed at our Philadelphia hospital had
a lower prevalence of vitamin D deficiency compared to
patients diagnosed at Zion and Tulsa hospitals. In
addition, patients with vitamin D deficiency had lower
serum albumin levels compared to those with non-
deficient serum vitamin D levels, the finding being border-
line significant (p = 0.06). Similarly, well-nourished pa-
tients had a lower prevalence of vitamin D deficiency
compared to malnourished patients, the finding being bor-
derline significant (p = 0.07).
Median survival
Table 2 shows the median survival times as a function of
various clinical and demographic variables. There was
no statistically significant difference in the Kaplan-Meier
median survival times across the 2 categories of serum
vitamin D, as displayed in Fig. 1. Gender, stage of dis-
ease, CTCA hospital, histologic subtype, SGA, ECOG
performance status and smoking status were significantly
associated with survival. Females, patients with stage III
disease, well-nourished patients, patients with ECOG
score 0–1 and patients with no smoking history had a
significantly greater median survival compared to males,
patients with stage IV disease, patients with ECOG score
2–4, and smoking history respectively. Patients with
adenocarcinoma and squamous cell carcinoma had a sig-
nificantly greater median survival compared to those
with cancers in the “others” category. Finally, patients
treated at our Philadelphia hospital had a significantly
greater median survival compared to those treated at
Zion and Tulsa hospitals.
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To further understand the differences in survival
across the 3 hospitals, we evaluated the distribution of
baseline clinical and demographic characteristics strati-
fied by the hospital (detailed results not shown in the
interest of space). The Philadelphia cohort (66 %) had a
significantly greater proportion of females compared to
the Zion (47.6 %) and Tulsa (42.5 %) cohorts; p = 0.04.
The Philadelphia cohort (66.7 %) also had a significantly
Table 1 Patient characteristics for the overall population as well as stratified by 2 serum vitamin D categories
Categorical variables Overall population (n = 359) Deficient: <20 ng/ml (n = 151) Not deficient: > = 20 ng/ml (n = 208) P-value
Gender 0.85
Male 181 77 (42.5) 104 (57.5)
Female 178 74 (41.6) 104 (58.4)
Stage 0.90
III 94 39 (41.5) 55 (58.5)
IV 265 112 (42.3) 153 (57.7)
CTCA hospital 0.04*
Philadelphia, PA 50 13 (26) 37 (74)
Zion, IL 269 119 (44.2) 150 (55.8)
Tulsa, OK 40 19 (47.5) 21 (52.5)
Histologic subtypea 0.90
Adenocarcinoma 268 114 (42.5) 154 (57.5)
Squamous cell 67 28 (41.8) 39 (58.2)
Others 19 9 (47.4) 10 (52.6)
SGAa 0.07
Well-nourished 211 81 (38.4) 130 (61.6)
Moderately-severely malnourished 124 60 (48.4) 64 (51.6)
ECOG scorea 0.02*
0–1 233 88 (37.8) 145 (62.2)
2–4 102 52 (51) 50 (49)
Season of diagnosis 0.004*
Summer 93 34 (36.6) 59 (63.4)
Fall 90 27 (30) 63 (70)
Winter 72 34 (47.2) 38 (52.8)
Spring 104 56 (53.8) 48 (46.2)
Smoking Statusa 0.006*
Never 69 27 (39.1) 42 (60.9)
Former 143 49 (34.3) 94 (65.7)
Current 143 75 (52.4) 68 (47.6)
Vitamin D supplementation at diagnosis 0.92
Yes 163 69 (42.3) 94 (57.7)
No 196 82 (41.8) 114 (58.2)
Continuous variables Overall population (n = 359) Deficient: <20 ng/ml (n = 151) Not deficient: > = 20 ng/ml (n = 208) P-value
Mean (SD) age (years) 57.4 (8.4) 57.1 (7.4) 57.6 (9.0) 0.62
Mean (SD) vitamin D (ng/ml) 25.5 (15.3) 13.3 (4.1) 34.4 (14.3) <0.001*
Mean (SD) BMI (kg/m2) 25.8 (5.7) 25.5 (5.9) 26 (5.7) 0.43
Mean (SD) serum albumin (g/dl) 3.6 (0.57) 3.5 (0.57) 3.6 (0.57) 0.06
(SGA Subjective Global Assessment, ECOG Eastern Cooperative Oncology Group, CTCA Cancer Treatment Centers of America, PA Pennsylvania, IL Illinois,
OK Oklahoma, BMI Body Mass Index, g/dl grams per deciliter, ng/ml nanograms per milliliter, kg/m2 kilograms per meter squared, SD Standard Deviation)
*P < = 0.05, Values in parentheses are row percentages
aMissing data (Histology = 5; SGA = 24; ECOG = 24; Smoking status = 4)
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greater proportion of well-nourished patients compared
to the Tulsa cohort (45 %); p = 0.04. Further, the
Philadelphia cohort (24 %) had a significantly smaller
proportion of current smokers compared to the Zion
(42.3 %) and Tulsa (47.5 %) cohorts; p = 0.002. Finally,
the mean baseline serum albumin in the Philadelphia
cohort (4.1 grams per deciliter [g/dl]) was significantly
higher compared to the Zion (3.4 g/dl) and Tulsa
(3.6 g/dl) cohorts; p <0.001. There were no systematic
differences among the 3 hospitals with regard to age, stage
at diagnosis, BMI and ECOG performance status.
The systematic differences among the 3 hospitals with
regard to gender, nutritional status, smoking status and
serum albumin might, in part, explain the observed dif-
ferences in median survival.
Univariate and multivariate survival analysis
Table 3 summarizes the results of univariate and multi-
variate Cox regression analyses. In the univariate analysis,
each predictor was tested in isolation for its association
with survival. Gender, stage of disease, CTCA hospital,
histologic subtype, SGA, ECOG performance status,
smoking status, BMI and serum albumin were signifi-
cantly associated with survival. Every 1 kilograms per
meter squared (kg/m2) increase in BMI was associated
with a 3 % reduction in mortality hazard (HR = 0.97;
p = 0.008) and every 1 g/dl increase in serum albumin
was associated with a 56 % reduction in mortality
hazard (HR = 0.44; p <0.001). In the full model, all
variables tested in the univariate analysis were evalu-
ated simultaneously in the same model. Six variables
demonstrated statistically significant associations with
survival: stage of disease, CTCA hospital, histologic
subtype, SGA, smoking status and serum albumin.
Every 1 g/dl increase in serum albumin was associated
with a 54 % reduction in mortality hazard (HR = 0.46;
p < 0.001). In the final model, only those 6 variables
that were statistically significant in the full model
were evaluated together. All of them excepting histo-
logic subtype were found to be statistically significant.
To account for potential sampling bias and further in-
vestigate the stability of the classical multivariate Cox
model reported in Table 3, we conducted a bootstrap re-
sampling procedure based on 1000 samples. We did not
find any significant differences in regression coefficients
and their corresponding p values between the classical
Cox regression and bootstrap Cox regression models.
Discussion
We investigated the association between serum 25(OH)D
and survival in newly diagnosed stages III-IV NSCLC pa-
tients. The findings of our study add to the growing body
of literature on the potential association between serum
vitamin D and survival in NSCLC.
Consistent with the findings published by Heist et al.
[21], Anic et al. [23] and Turner et al. [22] we did not
find a significant association between serum vitamin D
and survival in our cohort of newly diagnosed advanced
NSCLC patients. The lack of a significant association
Table 2 Median survival as a function of patient characteristics
Categorical variables Median survival
in months
95 % CI P-value
Serum vitamin D 0.06
> = 20 ng/ml 12.8 10.8–14.7








Philadelphia, PA 38.2 4.1–72.3
Zion, IL 12.4 10.6–14.1
Tulsa, OK 7.4 4.2–10.5
Histologic subtype 0.002*
Adenocarcinoma 12.8 11.2–14.4
























(SGA Subjective Global Assessment, ECOG Eastern Cooperative Oncology
Group, CTCA Cancer Treatment Centers of America, PA Pennsylvania, IL Illinois,
OK Oklahoma, ng/ml nanograms per milliliter, CI Confidence Interval)
*P < = 0.05
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between serum vitamin D and survival in our study
could be explained in several ways. First, the disease was
far too advanced in our patients for vitamin D levels to
have any impact on prognosis. Second, the vitamin D
levels in our study were perhaps too low to have any sig-
nificant impact on the prognosis. Lastly, vitamin D may
not have any true impact on survival in advanced
NSCLC. Collectively, the results of our study considered
against the backdrop of the existing literature in this
area suggest that serum vitamin D levels measured ei-
ther pre- or post-diagnosis might not be independently
predictive of survival in advanced NSCLC cancer after
controlling for the most Season of diagnosis, ECOG per-
formance status, smoking status and hospital location
were found to be statistically significantly associated with
serum vitamin D levels. Patients diagnosed in the sum-
mer and fall months were less likely to be deficient in
vitamin D compared to those diagnosed in winter and
spring, a finding that has been widely reported in the lit-
erature. However, the mean serum vitamin D levels
across all 4 seasons were less than 32 ng/ml, a level con-
sidered to be sufficient [12, 14]. As a result, consistent
with the previous literature [18], the patients in our co-
hort were not exposed to enough sunlight even during
the summer months, and therefore had low circulating
25(OH)D levels. Patients with good performance status
were less likely to be deficient in vitamin D compared to
those with poor performance status. This finding is not
surprising because patients with good performance sta-
tus can be assumed to be more physically active
compared to those with poor performance status. We
found that current smokers had a greater prevalence of
vitamin D deficiency compared to past or no smokers.
By contrast, the study by Anic et al. did not report an as-
sociation between smoking status and serum vitamin D
[23]. There is little information in the literature on the
potential biologic mechanisms underlying the relation-
ship between smoking status and serum vitamin D
levels. However, given the findings of our study, smoking
status is clearly an important covariate to include in all
studies evaluating the role of serum vitamin D in pre-
dicting mortality in all tobacco-related cancers such as
NSCLC. Finally, patients diagnosed at our Philadel-
phia hospital had a lower prevalence of vitamin D de-
ficiency compared to patients diagnosed at Zion and
Tulsa hospitals. This could potentially be attributed
to referral bias or might reflect geographic variation
in serum vitamin D distribution.
Two predictors demonstrated borderline significance
in their association with serum vitamin D levels: serum
albumin and nutritional status. Patients with vitamin D
deficiency had lower serum albumin levels compared to
those with non-deficient serum vitamin D levels, and
well-nourished patients had a lower prevalence of vita-
min D deficiency compared to malnourished patients;
both findings consistent with our recently reported re-
search in prostate cancer [17].
In contrast with previously published research [13,
28–30], we did not find lower serum levels of 25(OH)D
to be associated with higher BMI. Multiple mechanisms
Fig. 1 Overall survival stratified by baseline serum 25(OH)D categories. There was no statistically significant difference in the median survival
times across the 2 categories of serum vitamin D
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have been proposed to explain the association of obes-
ity with hypovitaminosis D, including lack of sunlight
exposure from physical inactivity [31] and sequestration
of vitamin D in subcutaneous fat depots [32] As a re-
sult, it has been proposed that BMI should be taken
into account when assessing a patient’s vitamin D status
and more aggressive vitamin D supplementation should
be considered in obese cancer patients [30]. This lack
of association between serum vitamin D and BMI in
our study could be due to a lack of significant variabil-
ity in BMI levels given our patients’ advanced disease
status.
Table 3 Univariate and multivariate Cox regression analyses of the relationship between serum vitamin D and survival
Variables Univariate model HR (95 % CI) Full model HR (95 % CI) Final model HR (95 % CI)
Serum vitamin D
> = 20 ng/ml (reference)
<20 ng/ml 1.2 (0.9–1.6) 0.99 (0.8–1.3)
Gender
Female (reference)
Male 1.3 (1.01–1.6)* 1.1 (0.9–1.5)
Stage
III (reference)
IV 2.3 (1.8–3.1)* 2.3 (1.7–3.2)* 2.3 (1.7–3.1)*
CTCA hospital
Philadelphia, PA (reference)
Zion, IL 3.2 (1.8–5.8)* 1.9 (0.9–4.1) 2.0 (0.9–4.2)
Tulsa, OK 5.8 (3.0–11.2)* 4.0 (1.8–8.8)* 4.1 (1.9–8.9)*
Histologic subtype
Adenocarcinoma (reference)
Squamous cell 1.1 (0.8–1.4) 0.9 (0.6–1.3) 0.9 (0.7–1.3)
Others 2.3 (1.4–3.8)* 1.8 (1.02–3.2)* 1.7 (0.9–2.8)
SGA
Well-nourished (reference)
Moderately-severely malnourished 2.0 (1.6–2.6)* 1.4 (1.02–1.8)* 1.4 (1.1–1.9)*
ECOG score
0–1 (reference)
2–4 1.6 (1.2–2.1)* 1.2 (0.9–1.6)
Season of diagnosis
Summer (reference)
Fall 1.0 (0.7–1.4) 1.4 (0.9–1.9)
Winter 1.2 (0.9–1.7) 1.3 (0.9–1.8)
Spring 1.1 (0.8–1.5) 1.1 (0.8–1.6)
Smoking status
Never (reference)
Former 1.5 (1.1–2.1)* 1.4 (1.01–2.1)* 1.5 (1.1–2.2)*
Current 1.6 (1.1–2.1)* 1.3 (0.9–1.9) 1.4 (0.9–1.9)
Age (continuous) 1.0 (0.99–1.01) 1.01 (0.99–1.02)
Serum vitamin D (continuous) 1.0 (0.99–1.01)
BMI (continuous) 0.97 (0.95–0.99)* 0.99 (0.97–1.02)
Serum albumin (continuous) 0.44 (0.35–0.54)* 0.46 (0.34–0.61)* 0.46 (0.35–0.61)*
(SGA Subjective Global Assessment, ECOG Eastern Cooperative Oncology Group, CTCA Cancer Treatment Centers of America, PA Pennsylvania, IL Illinois,
OK Oklahoma, BMI Body Mass Index, ngcpaml nanograms per milliliter, HR Hazard Ratio, CI Confidence Interval)
*P < = 0.05
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In vitro and animal studies have shown that vitamin
D has antiproliferative, antimetastasis, and antiangio-
genesis activities in lung cancer and may modulate the
immune function of lung epithelial cells [18, 33–35]. In
human squamous cell carcinoma and lung cancer cell
lines and mouse models, 1,25-dihydroxyvitamin D has
been shown to inhibit the growth and angiogenesis of
tumor cells potentially due to the suppression of re-
sponse to vascular endothelial growth factor [35]. Also,
1, 25-dihydroxyvitamin D suppresses epidermal growth
factor receptor, which signals several tumorigenic pro-
cesses, such as proliferation and metastasis, in lung
cancer [36]. Finally, 1, 25-dihydroxyvitamin D has been
hypothesized to stimulate the secretion of protein
glues, such as E-cadherin and catenin, making cells
more adherent to each other thereby preventing metas-
tases [37].
There are some limitations of our study that are
worth acknowledging. This is an association study
which cannot prove causality. Reverse causality (the
effect of cancer on serum vitamin D levels) is always
a possibility in observational studies and cannot be
ruled out with certainty [38]. Potential confounding
by factors such as exercise, sunlight exposure and
dietary vitamin D intake cannot be ruled out, although
season of diagnosis was used as a proxy for sunlight ex-
posure. In this study, serum 25(OH)D was measured only
once at the time of diagnosis which might not be reflective
of vitamin D levels during cancer generation or progres-
sion. However, previous research has shown the reliability
of a single serum vitamin D assessment over a 5-year
period [28]. Similarly, smoking status was only available at
baseline based on the information provided by patients.
The treatments received were not standardized as they
would have been in a clinical trial setting. No formal sam-
ple size calculation was conducted before undertaking this
study. Finally, the available survival data could not distin-
guish between death from NSCLC and from other causes;
therefore, we assessed the all-cause mortality instead of
NSCLC-specific mortality.
There are some strengths of our study. We examined
a homogeneous patient population of newly diagnosed
advanced NSCLC which minimizes potential confound-
ing by tumor stage and prior treatment history. We
measured serum vitamin D at disease diagnosis prior to
receiving any treatment which eliminates the possibility
of treatment and lifestyle changes affecting serum vita-
min D levels after diagnosis. We had a large sample size
of histologically confirmed NSCLC cases. By using a
consecutive case series of all eligible patients seen at our
institution during a fixed time period, we minimized the
possibility of selection bias in our study. Lastly, we ad-
justed for a wide range of potential clinical and demo-
graphic confounders thereby minimizing the possibility
of residual confounding. That being said, the possibility
of residual confounding can never be completely ruled
out in observational studies.
Conclusion
In conclusion, we did not find any significant association
between serum 25(OH)D and survival in newly diag-
nosed stages III-IV NSCLC patients. This finding needs
further exploration in future prospective studies of larger
sample sizes across all stages of NSCLC.
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